Table 1. Descriptions of archetypes from the P2I v.1 model.
| Archetype | Description | Examples | |
|---|---|---|---|
| Vaccine | Simple | Platform has been used to develop other vaccines | Hepatitis A, hepatitis B, polio |
| Complex | Requires completely novel approach; no platform; no
existing research |
Pneumococcal conjugate vaccine
(PCV), meningitis B |
|
| New Chemical
Entity (NCE) |
Simple | Validated target or mechanism of action | Primaquine |
| Innovative | Novel target or mechanism of action with understanding
of disease pathogenesis |
Ibrutinib | |
| Complex | Novel target or mechanism of action without
understanding of disease pathogenesis |
Imatinib | |
| Repurposed
Drug |
Simple | Drug has sufficient safety data to start development in
Phase II |
Azithromycin, doxycycline |
| Complex | Drug requires some Phase I clinical trials to verify safety
in humans |
Moxidectin | |
| Biologic | Simple | Validated target or mechanism of action | IL-17 antibody |
| Complex | Novel target or mechanism of action | Natalizumab | |
| Diagnostics | Assay development | Development of a diagnostic assay | Lateral flow tests, quantitative
molecular tests |
| Simple technical
platform development |
Development of a technological platform that enhances
current technology |
Ultrasensitive malaria rapid
diagnostic test (RDT) |
|